Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Earnings Call

Travere Therapeutics Earnings Call: Key Takeaways

Travere achieved record quarterly revenue of $220.2 million, driven by Filspari's expansion into FSGS, though management faces a CEO transition and increased competition in the IgA nephropathy market.

Full earnings call on the Alfa Finder USA YouTube channel · Open on YouTube ↗
Highlights
Revenue GrowthFilspari $200.2M (up 120% YoY); Thiola/Buphenyl $20M; Total revenue $224.6M.
Mgmt ConfidenceHigh confidence in $3B target; CEO transition described as 'position of strength'.
Demand Visibility1,932 new patient start forms in Q3 across IgAN and FSGS.
Order BookSpecialty pharmacy inventory increased $8M above historical levels in Q3.
Margin TrendsGross-to-net discounts expected in mid-20% range for full year.
Op. LeverageR&D and SG&A expenses totaled $168.7M; scaling with FSGS launch.
Vol vs PriceGrowth driven by new patient starts and FSGS indication expansion.
Segment GrowthFSGS launch showing strong demand; IgAN seeing 'small decrease' in starts.
New Clients40% of FSGS prescribers were new to Filspari this quarter.
Capex & Debt$471.8M cash; $112.5M upfront payment for Everest licensing agreement.
RegulatoryUS IND for sparsentan-alternative (Ceborebrutinib) planned by year-end 2026.
CommentaryEmphasized Filspari as 'foundational kidney-targeted therapy' complementary to B-cell inhibitors.
New LaunchesFSGS indication launched; Sparlight Phase 4 study initiating late 2026.

Growth

Total revenue $224.6M; Filspari net sales $200.2M, up 120% year-over-year.

Outlook

Targeting $3 billion in annual Filspari sales by 2033; HCU top-line results 2H 2027.

Risks

Management pivoted to qualitative 'dynamism' language when pressed on sequential IgAN patient start form declines.

Source

The company's earnings call, NASDAQ: TVTX, and its 8-K filed with the SEC. Summary written with AI assistance from the call.

Read the 8-K ↗

Travere Therapeutics, Inc.: key numbers

Share price
$49.70Close, Nov 16
Market cap
$4.77B
Shares outstanding
95.99MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Travere Therapeutics, Inc.

All →
4:06 PM ET 8-K
Financial Results

Travere Therapeutics Financial Results

Travere Therapeutics reported Q3 2026 financial results, highlighted by $200.2 million in FILSPARI net product sales, representing 120% year-over-year growth. The company is advancing its Phase 3 HARMONY study of pegtibatinase with topline results expected in the second half of 2027 and plans to submit an IND for civorebrutinib by year-end.

“Strong execution across our business drove another quarter of significant growth, with FILSPARI net product sales of $200 million for the quarter as we continued to expand our reach in IgAN and FSGS.”

Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics

“As I prepare to transition leadership to Bradley Campbell in December, I have never been more confident in Travere’s future, supported by an exceptional team, an expanding pipeline and a shared commitment to delivering hope to patients.”

Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics
4:05 PM ET Form 4
Insider Selling

Travere Therapeutics CEO Eric M. Dube Sells $13.1M of Stock

Eric M. Dube, CEO, sold 243,735 shares of Travere Therapeutics, Inc. at $52.97 to $55.02 a share (average $53.82) in 3 transactions, worth $13.1M in total on Oct 15, 2026. Shares held after the trade: 432,886 (-15.3%).

Value
$13.1M
Shares
243,735
Average price
$53.82
Role
CEO
Holding change
-15.3%
Trade date
Oct 15, 2026
4:11 PM ET 8-K
Leadership Change

Travere Therapeutics Leadership Change

Travere Therapeutics announced that Eric Dube, Ph.D., will step down as President, CEO, and Board member effective December 1, 2026. Bradley L. Campbell, former CEO of Amicus Therapeutics, has been appointed as his successor. Dr. Dube will remain as an Executive Advisor through February 15, 2027, to facilitate a smooth leadership transition.

Counterparty
Bradley L. Campbell

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.